NEW HAVEN, Conn., Feb. 23, 2021 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a
commercial-stage biopharmaceutical company with a portfolio of
innovative, late-stage product candidates targeting neurological
and neuropsychiatric diseases, will host a conference call and
webcast to report fourth quarter and full year 2020 financial
results and provide a review of recent accomplishments and
anticipated upcoming milestones, on Monday
March 1, 2021 at 8:30 a.m.
ET.
To access the call, please dial 877-407-9120 (domestic) or
412-902-1009 (international). The conference call webcast and
accompanying slide presentation can be accessed through the
"Investors" section of Biohaven's website at
www.biohavenpharma.com. To ensure a timely connection, it is
recommended that participants register at least 15 minutes prior to
the scheduled webcast. A replay of the call will be made available
for two weeks following the conference call. To hear a replay of
the call, dial 877-660-6853 (domestic) or 201-612-7415
(international) with conference ID 13715754. An archived webcast
will be available on Biohaven's website.
About Biohaven
Biohaven is a commercial-stage
biopharmaceutical company with a portfolio of innovative,
best-in-class therapies to improve the lives of patients with
debilitating neurological and neuropsychiatric diseases, including
rare disorders. Biohaven's neuroinnovation portfolio includes
FDA-approved NURTEC® ODT (rimegepant) for the acute
treatment of migraine and a broad pipeline of late-stage product
candidates across three distinct mechanistic platforms: CGRP
receptor antagonism for the acute and preventive treatment of
migraine; glutamate modulation for obsessive-compulsive
disorder, and spinocerebellar ataxia; and myeloperoxidase
(MPO) inhibition for multiple system atrophy and amyotrophic
lateral sclerosis. More information about Biohaven is available at
www.biohavenpharma.com.
NURTEC is a trademark of Biohaven Pharmaceutical Ireland
DAC.
Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-to-report-fourth-quarter-and-full-year-2020-financial-results-and-recent-business-developments-on-march-1-2021-301234050.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.